In The Lancet HIV, Jean-Michel Molina and colleagues present 96-week data on doravirine (100 mg), a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), versus darunavir (800 mg) boosted with ritonavir (100 mg) once daily, both in combination with investigator-selected nucleoside reverse transcriptase inhibitors (NRTIs)—emtricitabine and tenofovir disoproxil fumarate or abacavir and lamivudine—for initial treatment of HIV-1 infection. Interestingly, the authors compared doravirine with a boosted protease inhibitor in patients who were treatment naive, although highly effective and potent integrase strand inhibitors were a recommended first-line option in many guidelines by the time of trial commencement in 2014. ^, 

中文翻译：

---

96周的数据足以使doravirine前进吗？

Jean-Michel Molina及其同事在《柳叶刀》 HIV杂志中介绍了一种新的非核苷类逆转录酶抑制剂（NNRTI）多拉维林（100毫克）与每日一次利托那韦（100毫克）强化治疗的地那那韦（800毫克）的96周数据，与研究者选择的核苷逆转录酶抑制剂（NRTIs）联合使用-恩曲他滨和替诺福韦富马酸替诺福韦酯或阿巴卡韦和拉米夫定-最初用于治疗HIV-1感染。有趣的是，作者在未接受过治疗的患者中将多拉维林与一种增强的蛋白酶抑制剂进行了比较，尽管在2014^年 开始试验时，许多指南中都建议将高效有效的整合酶链抑制剂作为一线治疗方案。